GeneDx Holdings Corp.
WGS
$98.01
$0.740.76%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 54.43% | 31.73% | 3.66% | -0.82% | -13.94% |
| Total Other Revenue | -52.36% | -39.62% | -16.37% | -3.64% | -6.09% |
| Total Revenue | 50.79% | 29.41% | 3.06% | -0.91% | -13.69% |
| Cost of Revenue | -2.15% | -34.14% | -46.84% | -53.76% | -56.29% |
| Gross Profit | 118.16% | 277.05% | 311.51% | 829.94% | 459.05% |
| SG&A Expenses | -12.83% | -27.80% | -40.27% | -46.77% | -43.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -30.92% | -43.39% | -25.11% | -17.55% | 49.59% |
| Total Operating Expenses | -10.42% | -31.87% | -41.75% | -47.62% | -47.13% |
| Operating Income | 86.78% | 80.72% | 75.52% | 72.25% | 64.36% |
| Income Before Tax | 70.21% | 81.66% | 76.07% | 76.66% | 70.45% |
| Income Tax Expenses | 62.96% | -71.76% | -168.87% | 98.25% | 98.11% |
| Earnings from Continuing Operations | 70.25% | 81.80% | 76.22% | 74.67% | 67.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 70.25% | 81.80% | 76.22% | 74.67% | 67.98% |
| EBIT | 86.78% | 80.72% | 75.52% | 72.25% | 64.36% |
| EBITDA | 99.67% | 88.62% | 81.96% | 77.90% | 69.86% |
| EPS Basic | 73.59% | 90.34% | 88.12% | 88.20% | 85.50% |
| Normalized Basic EPS | 78.96% | 81.95% | 81.87% | 85.45% | 82.63% |
| EPS Diluted | 73.59% | 90.34% | 88.12% | 88.20% | 85.50% |
| Normalized Diluted EPS | 78.96% | 81.95% | 81.87% | 85.45% | 82.63% |
| Average Basic Shares Outstanding | 10.67% | 27.35% | 51.85% | 92.66% | 137.60% |
| Average Diluted Shares Outstanding | 10.67% | 27.35% | 51.85% | 92.66% | 137.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
